CME Group (CME) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
3 Mar, 2026Competitive advantages and product diversity
Broad product suite spans interest rates, equity index, energy, agricultural, metals, FX, and cryptocurrency, supporting diverse risk management needs.
Deep liquidity pools and a healthy ecosystem of varied market participants drive unmatched capital efficiencies.
Proprietary market data and technology investments, including a strategic partnership with Google Cloud, enhance trading and customer acquisition.
Global sales organization with significant presence outside the U.S. and a focus on customer-driven innovation.
Financial performance and growth
Achieved 8% revenue growth and 10% earnings growth year-over-year in Q4 2025, with a 67.1% adjusted operating margin.
Record average daily volume (ADV) for the fifth consecutive year in 2025, with notable growth in metals (114%) and equity index (22%).
Non-U.S. ADV reached 9.6 million in 2026 to date, with 60% of front office sales staff outside the U.S.
Adjusted net income for 2025 was $4.09 billion, with a total revenue of $6.52 billion and a 69.4% operating margin.
Product innovation and customer growth
Significant ADV growth in new products, including 32% in micros and 11% in OTC alternatives in 2025.
Retail customer base nearly quadrupled over the past decade, with 23% growth in 2025 and 46% of participants from outside the U.S.
Launched new retail partnerships and products, including a joint venture with FanDuel and expanded micro contracts.
Leading position in battery metals, voluntary carbon, and cryptocurrency derivatives.
Latest events from CME Group
- Shareholders will vote on director elections, auditor ratification, and key governance amendments.CME
Proxy filing23 Mar 2026 - Shareholders to vote on major governance reforms, executive pay, and director elections.CME
Proxy filing23 Mar 2026 - Proposal to eliminate Class B director election rights, with payments to affected shareholders.CME
Proxy Filing12 Mar 2026 - Shareholders to vote on eliminating Class B director election rights amid record financial performance.CME
Proxy Filing12 Mar 2026 - Global growth, product innovation, and high margins drive record performance and shareholder returns.CME
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - Record revenue, earnings, and trading volumes in 2025, with strong capital returns.CME
Q4 20254 Feb 2026 - Record financials, all proposals approved, and strong outlook amid competition and litigation.CME
AGM 20253 Feb 2026 - Record Q2 revenue, net income, and trading volumes, with growth in every asset class and strong margins.CME
Q2 20243 Feb 2026 - Strong volumes and global uncertainty drive growth focus in equities and credit, with regulatory vigilance.CME
Piper Sandler Global Exchange and Trading Conference 20241 Feb 2026